NCT03448692
A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS) No drug interventions treatment 2 terminated NCT05955872
A Study Evaluating the Relative Bioavailability and Food Effect of a Tablet Formulation of VX-147 No drug interventions treatment 1 completed NCT00550342
Rituximab Treatment of Focal Segmental Glomerulosclerosis treatment 2 completed NCT00001959
Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis) treatment 2 completed NCT00302536
Tacrolimus Treatment of Patients With Idiopathic Focal Segmental Glomerulosclerosis treatment Not Available withdrawn NCT00193648
Pilot Studies of Novel Therapies to Treat Resistant Focal Segmental Glomerulosclerosis (FSGS) treatment 1 completed NCT00040508
Sirolimus for Focal Segmental Glomerulosclerosis treatment 2 completed NCT00404833
Mycophenolate Mofetil in Membranous Nephropathy and Focal Segmental treatment 3 completed NCT00353535
Total Lymphoid Irradiation (TLI) to Prevent Focal Segmental Glomerulosclerosis (FSGS)Recurrence in the Renal Graft No drug interventions treatment 1 completed NCT00135811
Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT) treatment 3 completed NCT01240564
The Nephrotic Syndrome Study Network (NEPTUNE) No drug interventions Not Available Not Available recruiting NCT00464321
Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS treatment 1 completed NCT06500702
A Study to Evaluate the Efficacy and Safety of Frexalimab, SAR442970, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease treatment 2 not_yet_recruiting NCT00001393
Genetic Markers for Focal Segmental Glomerulosclerosis No drug interventions Not Available Not Available completed NCT03493685
Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS) treatment 3 active_not_recruiting NCT06065852
National Registry of Rare Kidney Diseases No drug interventions Not Available Not Available recruiting NCT00956059
Therapeutic Effect of Low-dose Prednisone Combined With MMF and FK506 in Focal Segmental Glomerulosclerosis treatment Not Available unknown_status NCT00007475
Permeability Factor in Focal Segmental Glomerulosclerosis treatment 1 / 2 completed NCT02896270
Valproic Acid for Idiopathic Nephrotic Syndrome treatment 2 / 3 unknown_status NCT01613118
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis treatment 2 completed NCT05650619
Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease No drug interventions Not Available Not Available recruiting NCT04571658
NEPTUNE Match Study No drug interventions Not Available Not Available enrolling_by_invitation NCT05588063
taVNS for FRNS in Children No drug interventions treatment Not Available recruiting NCT05942625
A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects No drug interventions treatment 1 recruiting NCT02235857
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children No drug interventions treatment Not Available recruiting NCT05441826
Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS) treatment 2 terminated NCT02382874
Allogenic AD-MSC Transplantation in Idiopathic Nephrotic Syndrome (Focal Segmental Glomerulosclerosis) No drug interventions treatment 1 unknown_status NCT04573920
Atrasentan in Patients With Proteinuric Glomerular Diseases treatment 2 active_not_recruiting NCT02194582
Genetic Causes of FSGS, Nephrotic Syndrome, or Kidney Failure No drug interventions Not Available Not Available active_not_recruiting NCT06090227
AMPK-activation by Metformin in FSGS: AMP-FSGS treatment 1 / 2 recruiting NCT05267262
Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis treatment 2 recruiting NCT02585804
Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects treatment 4 completed NCT04065438
Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System No drug interventions treatment Not Available recruiting NCT03763643
PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant prevention 0 recruiting NCT03929887
KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis No drug interventions Not Available Not Available recruiting NCT03536754
A Study of CCX140-B in Subjects With FSGS treatment 2 completed NCT03298698
Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome treatment 3 unknown_status NCT00255398
Kidney Disease Biomarkers No drug interventions Not Available Not Available completed NCT02592798
Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD) treatment 2 completed NCT04369183
Rituximab for Refractory or Relapsed Focal Segmental Glomerulosclerosis or Minimal Change Disease No drug interventions Not Available Not Available completed NCT00782561
Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS) treatment 1 terminated NCT05200871
Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy) No drug interventions Not Available Not Available completed NCT00816478
Effect of Oral Galactose on Focal Segmental Glomerulosclerosis (FSGS) Permeability Factor treatment 1 terminated NCT01113385
Oral Galactose in Children With Steroid Resistant Nephrotic Syndrome treatment Not Available completed NCT03366337
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX treatment 2 completed NCT03649152
Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving Irbesartan treatment 2 completed NCT01370200
Regional Citrate Anticoagulation in Plasma Exchange Treatment No drug interventions treatment Not Available completed NCT05583942
A Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS) No drug interventions treatment Not Available recruiting NCT04088799
LDL-Apheresis for FSGS CardioRenal Outcomes No drug interventions Not Available Not Available completed NCT03598036
Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental Glomerulosclerosis treatment 2 terminated NCT00883636
Cardiomyopathy in Steroid-resistant Nephrotic Syndrome: Impact of Focal Segmental Glomerulosclerosis No drug interventions Not Available Not Available terminated NCT06443034
Predictive Determinants of Nephrotic Syndrome Remission in Patients With At-risk Polymorphism of APOL1 No drug interventions Not Available Not Available not_yet_recruiting NCT00801463
Prednisone Plus Tripterygium Wilfordii Treatment of Adult Patients With Idiopathic Focal Segmental Glomerulosclerosis treatment Not Available completed NCT05003986
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases treatment 2 recruiting NCT01129557
Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease treatment 4 terminated NCT02693366
Stem Cell Therapy for Patients With Focal Segmental Glomerulosclerosis No drug interventions treatment 1 completed NCT03126201
Predictors of Disease Progression in Primary Focal Segmental Glomerulosclerosis No drug interventions Not Available Not Available completed NCT00816504
Effect of Galactose on Permeblity Factor in Patients With FSGS and CKD Stage 5 treatment 1 withdrawn NCT04009668
Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease basic_science 2 completed NCT06162546
ARREST-NEPHROSIS - Austrian Resistant Nephrotic Syndrome Treatment Response Registry and Biobank No drug interventions Not Available Not Available recruiting NCT00814255
Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial treatment 2 completed NCT03703908
A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome treatment 2 terminated NCT01209000
Nephrotic Syndrome Study Network No drug interventions Not Available Not Available recruiting NCT05505500
Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome. No drug interventions Not Available Not Available recruiting NCT02000440
A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS) treatment 2 completed NCT03949972
The FOrMe Registry (The German Focal Segmental Glomerulosclerosis and Minimal Change Disease Registry) No drug interventions Not Available Not Available recruiting NCT04235621
A Study to Understand the Genetics and Clinical Course of Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN) No drug interventions Not Available Not Available terminated NCT04387448
A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease No drug interventions treatment 2 terminated NCT00098020
Podocyte Retinoids treatment 2 completed NCT04340362
Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis No drug interventions treatment 2 completed